Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Infect Dis ; 65(7): 1214-1217, 2017 10 01.
Article in English | MEDLINE | ID: mdl-28575220

ABSTRACT

We retrospectively analyzed a cohort of 109 subjects treated for recurrent Clostridium difficile infection with fecal microbiota transplantation (FMT) at a tertiary referral center between 2011 and 2014 to determine risk factors for FMT failure. In a multivariate analysis, failure to use an oral vancomycin taper preceding FMT was associated with a significant risk of FMT failure (odds ratio, 0.15; 95% confidence interval, .007-.40).


Subject(s)
Anti-Bacterial Agents/therapeutic use , Clostridioides difficile/drug effects , Clostridium Infections/drug therapy , Feces/microbiology , Vancomycin/therapeutic use , Adult , Aged , Aged, 80 and over , Fecal Microbiota Transplantation/methods , Female , Humans , Male , Microbiota/physiology , Middle Aged , Recurrence , Retrospective Studies , Risk Factors , Treatment Outcome , Young Adult
2.
Expert Rev Respir Med ; 10(10): 1079-91, 2016 10.
Article in English | MEDLINE | ID: mdl-27635942

ABSTRACT

INTRODUCTION: Coccidioidomycosis is an endemic fungal infection caused by the soil-dwelling fungi, Coccidioides species. Coccidioidal infections may be asymptomatic in up to two-thirds of infected persons. Pulmonary coccidioidomycosis is the most common form of symptomatic infection. Fluconazole is the antifungal agent typically used to treat pulmonary coccidioidomycosis. Other azoles and amphotericin B products may be prescribed to treat nuanced aspects of coccidioidomycosis. AREAS COVERED: This review discusses current literature regarding medical treatment options, including the various triazoles and amphotericin B products. In addition, we discuss uncomplicated and complicated pulmonary infections and their sequelae and the approach to managing coccidioidomycosis in certain populations of patients, such as pregnant women, transplant recipients, individuals infected with human immunodeficiency virus, and recipients of tumor necrosis factor-α inhibitors. Expert commentary: Symptomatic coccidioidomycosis can present physicians with a number of challenges, including the lack of sensitivity and specificity of diagnostic tests and lack of a standard treatment approach for all patients with the infection. Ongoing and future clinical trials will determine the optimal diagnostic, therapeutic, and prophylactic approaches, particularly for patients with comorbid conditions.


Subject(s)
Antifungal Agents/therapeutic use , Coccidioidomycosis/drug therapy , Lung Diseases, Fungal/drug therapy , Coccidioidomycosis/diagnosis , Humans , Lung Diseases, Fungal/microbiology
SELECTION OF CITATIONS
SEARCH DETAIL
...